Open AccessTacrolimus and mycophenolate mofetil as second-line treatment in autoimmune hepatitis: Is the evidence of sufficient quality to develop recommendations?
Author(s) -
Mohammadreza Abdollahi,
Neda Khalilian Ekrami,
Morteza Ghojazadeh,
H. Marike Boezen,
MohammadHossein Somi,
Behrooz Z. Alizadeh
Publication year - 2020
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v26.i38.5896
Subject(s) - mycophenolate , tacrolimus , medicine , autoimmune hepatitis , mycophenolic acid , immunology , intensive care medicine , hepatitis , transplantation
The standard management of autoimmune hepatitis (AIH) is based on corticosteroids, alone or in combination with azathioprine. Second-line treatments are needed for patients who have refractory disease. However, high-quality data on the alternative management of AIH are scarce.